You are here

Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Semmelweis University
Budapest, , H-1085 Hungary
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Plaque Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-99 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Clinical diagnosis of chronic plaque type psoriasis for at least 6 months as determined by
the subjects medical history, and confirmation of the diagnosis through physical
examination by the investigator Patients who are scheduled by their dermatologist to
initiate treatment with Etanercept

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Previous or current treatment with antipsoriatic biologic drugs, such as etanercept,
infliximab, adalimumab, ustekinumab, alefacept, efalizumab Chronic or acute infections
requiring intravenous or oral anti-infectives within 14 days prior to the Baseline visit

NCT02192164
Pfizer
Completed
Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Rheumatoid Arthritis, Psoriasis Arthritis
NCT01623752
All Genders
Chronic Plaque Psoriasis
NCT02969018
All Genders
18+
Years
Multiple Sites
Psoriatic Arthritis, Psoriasis, Papulosquamous Skin Diseases
NCT00293709
All Genders
18+
Years
Muenchen,
Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis
Non-interventional Study Of The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis
Pilot observational study to describe the relationship between the smoking status of a psoriatic individual and the success of etanercept therapy in psoriasis treatment
non-interventional study There is no sampling
Observational
Observational Model: Other
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
etanercept treated plaque psoriasis patients
Plaque Psoriasis
Behavioral: smoking questionnaire
patients fill in a smoking questionnaire about their smoking habits
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
126
May 2016
May 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Clinical diagnosis of chronic plaque type psoriasis for at least 6 months as determined by the subjects medical history, and confirmation of the diagnosis through physical examination by the investigator Patients who are scheduled by their dermatologist to initiate treatment with Etanercept

Exclusion Criteria:

Previous or current treatment with antipsoriatic biologic drugs, such as etanercept, infliximab, adalimumab, ustekinumab, alefacept, efalizumab Chronic or acute infections requiring intravenous or oral anti-infectives within 14 days prior to the Baseline visit

Sexes Eligible for Study: All
18 Years to 99 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Hungary
 
 
NCT02192164
B1801365
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now